---
title: Steer stimulation to reduce tremor
nct_id: NCT07700862
phase: NA
status: RECRUITING
sponsor: Ruijin Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07700862"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07700862"
last_fetched: "2026-07-14T14:00:05.136Z"
source: "Parkinson's Pathways (curated)"
---
# Steer stimulation to reduce tremor

**Goal (in five words):** Steer stimulation to reduce tremor

**Official Title:** Directional Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial

**Trial ID:** [NCT07700862](https://clinicaltrials.gov/study/NCT07700862)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Ruijin Hospital
- **Target Enrollment:** 32 participants
- **Start Date:** 2026-07-01
- **Completion Date:** 2028-12
- **Conditions:** Parkinsons Disease (PD)
- **Interventions:** directional Deep brain stimulation
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to see whether steering current to the posterior subthalamic area, versus to the subthalamic nucleus, better controls tremor in people with tremor-dominant Parkinson's disease. The approach implants directional deep brain stimulation leads that can steer electrical current, then after two months doctors do blinded mapping to find safe, effective settings and remove any setting that causes immediate, unmanageable side effects; participants with tolerated settings move into a randomized, blinded two-month crossover of each target, followed by a two-month open period where both targets are stimulated together, and everyone is followed up to 12 months after surgery. The trial is looking for adults 18 to 80 with idiopathic, tremor-dominant Parkinson's when off medication, with moderate disease (stage 2 to 4 on a standard Parkinson's scale when off meds), who have been on regular Parkinson's medicines for more than six weeks and can give informed consent. People with atypical parkinsonism, prior stroke or other major brain problems, significant cognitive or psychiatric illness, anatomical abnormalities at the target, or other medical issues that raise surgical risk are excluded.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is a crossover trial: instead of staying in one group, you move through a sequence of assignments, so you receive the active treatment during at least one period of the study. Ask the coordinator for the exact sequence and how long each phase lasts.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(From the protocol)_:
- Brain surgery / implanted device (Invasive)
  > "directional Deep brain stimulation"
- Surgical procedure (Invasive)
  > "All participants will then be followed-up up to 12 months after surgery."

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* diagnosis of idiopathic Parkinson's disease
* tremor-dominant subtype in the off-medication condition
* modified Hoehn-Yahr scale of 2 to 4 in the off-medication condition
* receiving regular anti-parkinsonian drugs for more than 6 weeks
* good compliance and written informed consent provided

Exclusion Criteria:

* Atypical parkinsonism
* History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery
* Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent
* Presence of anatomical abnormalities in the target region
* Clinically significant medical history that would increase pre-/post-operative complications
* Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data
```

## Locations (1)

- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China _(31.2222, 121.4581)_
  - Dianyou Li, MD, PhD, (CONTACT), +0086-021-64370045, ldy11483@rjh.com.cn

## Central Contacts

- Dianyou Li, MD, PhD, (CONTACT), +0086-021-64370045, ldy11483@rjh.com.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07700862*  
*HTML version: https://parkinsonspathways.com/trial/NCT07700862*  
*Source data: https://clinicaltrials.gov/study/NCT07700862*